TD Cowen Cuts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $153.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price trimmed by TD Cowen from $160.00 to $153.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Stifel Nicolaus lifted their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. JPMorgan Chase & Co. cut their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Finally, Wedbush reissued an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Trading Up 1.8 %

Shares of NASDAQ ASND opened at $126.51 on Friday. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of -15.66 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The company has a 50 day simple moving average of $132.30 and a two-hundred day simple moving average of $132.60.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. Analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in ASND. SG Americas Securities LLC purchased a new position in shares of Ascendis Pharma A/S in the first quarter worth about $288,000. ProShare Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 9.9% in the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 361 shares during the last quarter. Acadian Asset Management LLC lifted its position in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after buying an additional 234,446 shares in the last quarter. Bessemer Group Inc. grew its holdings in Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares in the last quarter. Finally, Nan Fung Group Holdings Ltd acquired a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth $2,056,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.